By Mark Bates, Ph.D.

As the field of mental health continues to evolve, psychedelic drugs are increasingly undergoing rigorous scientific research for their therapeutic potential. Molecules like psilocybin, MDMA, and DMT are being investigated in a variety of clinical trials, each with distinct protocols, dosages, and therapeutic approaches, aiming to understand efficacy for conditions ranging from depression and PTSD to anxiety in cancer patients. As anyone considering exploring psychedelic therapy—whether as a participant, therapist, or researcher—may already know, it is often expectations that most shape the experience.

Because psychedelic substances profoundly alter perception for extended periods, expectation-setting is critical as it helps ground participants when their usual sensory and cognitive frameworks are shifting, preventing confusion or distress that might arise from misinterpretations of the altered state.

Acknowledging potential disappointments up front within research environments can paradoxically create a more trusting environment for surrender and engagement. Addressing potential disappointment directly can allow difficult feelings to soften as they are discussed in a safe therapeutic context and metabolized. When disappointments do arise, they can become valuable opportunities for growth and integration.

Clinical trials differ from traditional therapy in their structured protocols and often limited post-dosing and post-trial support. Additionally, participants with past medical

© Psychology Today